Insider Selling: Roivant Sciences (NASDAQ:ROIV) Insider Sells $16,159,098.90 in Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) insider Frank Torti sold 587,390 shares of the company’s stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $27.51, for a total value of $16,159,098.90. Following the transaction, the insider directly owned 13,736,547 shares in the company, valued at $377,892,407.97. This trade represents a 4.10% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Frank Torti also recently made the following trade(s):

• On Thursday, February 19th, Frank Torti sold 1,400,000 shares of Roivant Sciences stock. The stock was sold at an average price of $27.42, for a total value of $38,388,000.00.
• On Friday, February 20th, Frank Torti sold 1,012,610 shares of Roivant Sciences stock. The stock was sold at an average price of $27.15, for a total value of $27,492,361.50.

Roivant Sciences Trading Up 1.4%

Roivant Sciences stock opened at $28.66 on Thursday. The company has a market cap of $20.51 billion, a PE ratio of -24.50 and a beta of 1.22. Roivant Sciences Ltd. has a 1 year low of $8.73 and a 1 year high of $29.20. The company’s 50-day moving average is $23.66 and its two-hundred day moving average is $19.26.

Institutional Investors Weigh In On Roivant Sciences

Large investors have recently modified their holdings of the business. Morgan Stanley raised its position in shares of Roivant Sciences by 31.7% during the fourth quarter. Morgan Stanley now owns 58,359,553 shares of the company’s stock worth $1,266,402,000 after purchasing an additional 14,036,696 shares during the period. Vanguard Group Inc. increased its stake in Roivant Sciences by 8.4% during the 4th quarter. Vanguard Group Inc. now owns 42,059,041 shares of the company’s stock worth $912,681,000 after purchasing an additional 3,254,113 shares in the last quarter. Rubric Capital Management LP raised its holdings in Roivant Sciences by 14.7% during the 2nd quarter. Rubric Capital Management LP now owns 20,370,336 shares of the company’s stock worth $229,574,000 after buying an additional 2,603,260 shares during the period. State Street Corp raised its holdings in Roivant Sciences by 4.8% during the 2nd quarter. State Street Corp now owns 19,773,480 shares of the company’s stock worth $222,847,000 after buying an additional 911,827 shares during the period. Finally, UBS Group AG lifted its stake in Roivant Sciences by 570.0% in the fourth quarter. UBS Group AG now owns 18,390,792 shares of the company’s stock valued at $399,080,000 after buying an additional 15,645,836 shares in the last quarter. 64.76% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

ROIV has been the subject of a number of analyst reports. Wall Street Zen raised shares of Roivant Sciences from a “strong sell” rating to a “hold” rating in a report on Sunday, November 16th. Weiss Ratings lowered Roivant Sciences from a “hold (c-)” rating to a “sell (d)” rating in a research report on Monday, February 9th. Guggenheim lifted their price objective on Roivant Sciences from $28.00 to $30.00 and gave the stock a “buy” rating in a research note on Monday, February 9th. TD Cowen reissued a “buy” rating on shares of Roivant Sciences in a research note on Saturday, February 7th. Finally, Leerink Partners raised their target price on Roivant Sciences from $29.00 to $32.00 and gave the stock an “outperform” rating in a report on Monday, December 15th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $28.69.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.